Overview

Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case reports in the literature. Hypophosphatemia in this context is attributed to an excess of FGF-23 (defect of degradation linked to carbohydrates in martial preparations) with renal leakage of phosphate.

Rendu-Osler disease (ROM) is an autosomal dominant genetic disease, favoring the formation of vascular malformations, including nasal and digestive telangiectasias causing repeated bleeding, even hemorrhages. Iron deficiency is frequent and profound there, and oral martial treatments are often insufficient to compensate for these losses. Regular iron infusions, to avoid transfusions, are often necessary.

Eligibility

Inclusion criteria:

• Major subject (≥ 18 years old)
• suffering from Rendu-Osler disease and receiving IV iron supplementation
• Subject not objecting, after information, to the reuse of their data for scientific research purposes

Exclusion criteria:

• Subject who expressed their opposition to participating in the study
• Subject under safeguard of justice
• Subject under guardianship or curatorship